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Abstract
The common participation of oncogenic KRAS proteins in many of the most lethal human 
cancers, together with the ease of detecting somatic KRAS mutant alleles in patient samples, has 
spurred persistent and intensive efforts to develop drugs that inhibit KRAS activity1. However, 
advances have been hindered by the pervasive inter- and intra-lineage diversity in the targetable 
mechanisms that underlie KRAS-driven cancers, limited pharmacological accessibility of many 
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candidate synthetic-lethal interactions and the swift emergence of unanticipated resistance 
mechanisms to otherwise effective targeted therapies. Here we demonstrate the acute and specific 
cell-autonomous addiction of KRAS-mutant non-small-cell lung cancer cells to receptor-
dependent nuclear export. A multi-genomic, data-driven approach, utilizing 106 human non-small-
cell lung cancer cell lines, was used to interrogate 4,725 biological processes with 39,760 short 
interfering RNA pools for those selectively required for the survival of KRAS-mutant cells that 
harbour a broad spectrum of phenotypic variation. Nuclear transport machinery was the sole 
process-level discriminator of statistical significance. Chemical perturbation of the nuclear export 
receptor XPO1 (also known as CRM1), with a clinically available drug, revealed a robust 
synthetic-lethal interaction with native or engineered oncogenic KRAS both in vitro and in vivo. 
The primary mechanism underpinning XPO1 inhibitor sensitivity was intolerance to the 
accumulation of nuclear IκBα (also known as NFKBIA), with consequent inhibition of NFκB 
transcription factor activity. Intrinsic resistance associated with concurrent FSTL5 mutations was 
detected and determined to be a consequence of YAP1 activation via a previously unappreciated 
FSTL5–Hippo pathway regulatory axis. This occurs in approximately 17% of KRAS-mutant lung 
cancers, and can be overcome with the co-administration of a YAP1–TEAD inhibitor. These 
findings indicate that clinically available XPO1 inhibitors are a promising therapeutic strategy for 
a considerable cohort of patients with lung cancer when coupled to genomics-guided patient 
selection and observation.
Extensive efforts have been directed at the identification of synthetic-lethal targets in KRAS-
mutant cancers, producing mixed results2–5. One obstacle may be the sampling error that is 
associated with phenotypic diversity among KRAS-mutant cancers, both between and within 
disease lineages. To examine this, we determined the KRAS mutation status of 106 non-
small-cell lung cancer (NSCLC)-derived cell lines (Supplementary Table 1). We then 
delineated common deterministic patterns derived from variations seen in whole-genome 
mRNA expression6 (Supplementary Table 2). At least eight phenotypic clusters were 
recovered, with KRAS-mutant cell lines present within most of them (Fig. 1a and Extended 
Data Fig. 1a). In fact, the variation in mRNA expression among KRAS-mutant cell lines was 
equivalent to that of all other cell lines in the panel (Extended Data Fig. 2a). To enrich for 
detection of bona fide synthetic-lethal genetic interactions with mutant KRAS, we therefore 
selected 12 cell lines, collectively distributed across the range of KRAS-independent 
background phenotypes, to serve as subjects for whole-genome short interfering RNA 
(siRNA) toxicity screens7,8 (Fig. 1a and Extended Data Fig. 1a). We detected 7,755 
candidate siRNA pools that reduced the viability of at least one KRAS-mutant line (using a 
Z score cut-off of −3; Fig. 1b and Supplementary Table 3). To mitigate noise from ‘off-
target’ siRNA oligonucleotide sequence-specific effects9, and to account for the complexity 
of KRAS-independent phenotypic variation, we used gene set enrichment analysis (GSEA; 
see Methods) to score gene sets, rather than individual genes, with collectively selective 
activity in the KRAS-mutant versus KRAS-wild-type lines. Of the 4,725 curated 
mechanistic gene sets queried, 10 were identified as being significantly enriched within the 
KRAS-mutant cohort (Fig. 1c and Extended Data Fig. 2b; false discovery rate (FDR) <0.2, P 
<1×10−16). Leading-edge analysis indicated that multiple genes that encode nuclear 
transport machinery were common among all 10 gene sets (Extended Data Fig. 2c–e). This 
enrichment was also seen in retrospective analysis of an independent short hairpin RNA 
Kim et al. Page 2
Nature. Author manuscript; available in PMC 2017 April 06.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
(shRNA) viability screen3 in an isogenic pair of KRAS-wild-type and KRASG12D colorectal 
cancer cell lines (Extended Data Fig. 2f). Among the nuclear transport components 
identified in the siRNA screen, the selective nuclear export receptor XPO1 has been 
previously identified as druggable10,11. We therefore tested the sensitivity to XPO1 depletion 
across an additional 55 cell lines and found a strong positive correlation with KRAS 
mutation status (Fig. 1d and Extended Data Fig. 2g, h).
These observations led us to consider selective sensitivity to inhibition of nuclear export as a 
mutant KRAS-associated vulnerability in lung cancer cells. To investigate this, we used the 
XPO1 inhibitors KPT-185 and KPT-330 (Selinexor)10,12,13 (Extended Data Fig. 3a). Given 
the phenotypic enrichment for short doubling times in KRAS-mutant cells (Extended Data 
Fig. 3b and Supplementary Table 4), we selected a test cohort of cells with equivalent 
proliferation rates. Significant selective dose sensitivity among the KRAS-mutant cell lines 
compared to KRAS-wild-type lines was observed with both compounds (Fig. 2a and 
Extended Data Fig. 3c–e). Sensitivity to XPO1 inhibitors was independent of cell doubling 
time (Extended Data Fig. 3f and Supplementary Table 4) and was completely rescued by the 
introduction of the drug-resistant mutation (C528S)12 using CRISPR/Cas9-induced 
homologous recombination (Fig. 2e and Extended Data Fig. 3g). The non-responsive A549 
cell line was an outlier and was therefore included in all subsequent analyses to represent 
potential mechanistic exceptions and/or contradictions to the KRAS synthetic-lethal theory.
Sensitivity to XPO1 inhibitors was associated with apoptosis (Fig. 2b, c), which was 
reversed by the XPO1C528S variant (Fig. 2e). This offered the opportunity to test clearance 
of stationary-phase cell populations using doses equivalent to those achievable in vivo with 
the orally bioavailable XPO1 inhibitor KPT-330 (ref. 14). With the exception of cell line 
A549, mutant KRAS-associated bimodal sensitivity to XPO1 inhibitors was evident (Fig. 
2d), with preservation of target selectivity at doses over 400% higher than bioactive in vivo 
concentrations (Extended Data Fig. 3h and Supplementary Table 5). Notably, expression of 
oncogenic KRAS was sufficient to sensitize lung epithelia to XPO1 inhibitors in both 
proliferative and stationary-phase cultures (Extended Data Fig. 3i). However, cell lines with 
activating mutations in NRAS were not sensitive to XPO1 inhibitors unless they carried a 
concurrent KRAS mutation (Extended Data Fig. 3j). Conservation of efficacy and selectivity 
in vivo was tested and confirmed using three different mouse tumour models: subcutaneous 
xenograft tumour models with both wild-type and mutant KRAS NSCLC lines, a 
KRASG12D patient-derived xenograft (PDX) model, and the KrasLSL-G12D,p53fl/fl (p53 is 
also known as Trp53) genetically engineered mouse (GEM) model (Fig. 2f–h and Extended 
Data Fig. 3k).
GSEA identified NFκB target genes as being enriched in the XPO1-inhibitor-sensitive 
cohort (Fig. 3a and Extended Data Fig. 4a), and NFκB target genes were highly 
overrepresented among the 50 most differentially expressed genes in the sensitive cohort 
when compared with the resistant cohort (Extended Data Fig. 4b, e). NFκB signalling is 
often activated by KRAS and can be required for KRAS-driven tumorigenesis2,15,16. 
Notably, XPO1 inhibition resulted in the time-dependent nuclear accumulation of the NFκB 
negative regulatory protein IκBα (Fig. 3b), inhibition of NFκB promoter activity (Fig. 3d) 
and inhibition of NFκB target-gene expression (Fig. 3c and Extended Data Fig. 4c, d). The 
Kim et al. Page 3
Nature. Author manuscript; available in PMC 2017 April 06.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
drug-resistant XPO1 allele cleanly reversed NFκB pathway sensitivity to KPT-185 (Fig. 3d). 
In addition, NFKBIA/B (the gene encoding IκBα/β) depletion was sufficient to confer 
resistance to XPO1 inhibitors (Fig. 3e and Extended Data Fig. 4f, g). These observations 
suggest that KRAS-mutant NSCLC cells require active nuclear export of IκBα to maintain 
NFκB-dependent survival signalling. Consistent with this, ectopic expression of an IκBα 
variant with an inactivated nuclear export signal (NES) sequence17 was tolerated in wild-
type but not KRAS-mutant NSCLC cells, reducing their viability (Extended Data Fig. 4h). 
Furthermore, sensitivity to treatment with the weak but specific IκB kinase inhibitor 
BMS-345541 (ref. 18) exhibited significant positive correlation with sensitivity to KPT-185 
(Extended Data Fig. 4i). In contrast, chemical inhibition of MEK activation, a key canonical 
KRAS pathway effector, had little consequence on cell viability at bioactive concentrations 
and showed no cooperativity with XPO1 inhibitors (Extended Data Fig. 4j, k). XPO1 
inhibitors induced the nuclear accumulation of IκBα in all cell lines tested (Extended Data 
Fig. 4l), indicating that selective sensitivity is likely to be due to context-specific 
consequences of inhibition of NFκB signalling rather than selective target inhibition. 
Consistent with this, we found that KPT-330-resistant tumours displayed extensive nuclear 
accumulation of IκBα in response to KPT-330 exposure in vivo (Fig. 3f). Together, these 
observations indicate that the oncogenic KRAS protein induces XPO1-dependent activation 
of NFκB signalling in NSCLC cells to support cell survival, but that activation of the NFκB 
pathway is not generally required for survival of KRAS-wild-type NSCLC tumour lines with 
alternative mechanistic drivers.
From separate pan-cancer cell line screening efforts, the KRAS-mutant NSCLC cell lines 
H2030 and H2122 were identified and validated as poor responders to XPO1 inhibitors 
(Extended Data Fig. 5a). We used this finding to identify any potential mechanisms of 
resistance to XPO1 inhibitors in KRAS-mutant NSCLC. On examination of whole-exome 
sequence data, we found that non- synonymous somatic alterations in FSTL5 selectively 
concur in XPO1-inhibitor-resistant KRAS-mutant lines (Fig. 4a and Supplementary Table 
6). Two previously untested KRAS-mutant cell lines, H2291 and H1573, had concurrent 
FSTL5 mutations and were both found to be robustly resistant to XPO1 inhibitors (Extended 
Data Fig. 5b, c). Somatic mutations in FSTL5 were detected in 10% of lung 
adenocarcinomas in the The Cancer Genome Atlas (TCGA) database (http://
www.cbioportal.org/), with an allelic distribution reminiscent of loss-of-function alterations 
(Extended Data Fig. 5d). Although mechanistically uncharacterized, FSTL5 has been 
nominated as a tumour suppressor protein in hepatocellular carcinoma (HCC)19 (Extended 
Data Fig. 5e). We found that FSTL5 depletion selectively reduced sensitivity to XPO1 
inhibitors in KRAS-mutant, FSTL5-wild-type NSCLC lines (Fig. 4b and Extended Data Fig. 
5f, g). Furthermore, ectopic FSTL5 expression was tolerated in wild-type but not mutant 
FSTL5 cell lines (Extended Data Fig. 5h), suggesting that some cancer genomes place 
selective pressure on FSTL5 inactivation. This suggests that FSTL5 mutations detected in 
cancer cells are loss-of-function and would promote resistance to XPO1 inhibitors.
Defective YAP signalling is a major contributory factor in the development of HCC20. 
Together with observations of YAP-dependent resistance mechanisms to Kras inhibition in 
mouse lung and pancreatic cancers21–23, this led us to evaluate the potential relationships 
between FSTL5 and YAP activity. Human lung adenocarcinomas (from the TCGA lung 
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adenocarcinoma database (TCGA-LUAD), n = 181) harbouring FSTL5 somatic alterations 
displayed significant increases in YAP1 protein expression when compared to wild-type 
tumours (Fig. 4c). Notably, FSTL5 depletion was sufficient to induce YAP1 protein 
stabilization (Fig. 4d and Extended Data Fig. 6a). Furthermore, transcription profiling 
revealed that the FSTL5-dependent gene expression programme was significantly enriched 
with genes that were also induced upon depletion of the LATS1 and LATS2 tumour 
suppressors (Extended Data Fig. 6b). To evaluate directly the FSTL5–YAP relationship in 
patient samples, 37 KRAS-mutant lung adenocarcinoma specimens were immunolabelled 
with antibodies for YAP1 (Supplementary Table 7). Slides were scored by experienced lung 
cancer pathologists for the percentage of YAP1-positive tumour cell nuclei and the relative 
YAP1 nuclear versus cytoplasmic distribution. Comparison to H2009 and H2030 cell blocks 
revealed three outlier tumours (1805, 1930 and 2279) with predicted YAP pathway 
activation (Fig. 4e and Extended Data Fig. 6c). Sanger sequencing of FSTL5 exons 
identified two samples that harboured somatic non-synonymous FSTL5 alterations (Fig. 4e 
and Extended Data Fig. 5d). These observations indicate a strong and clinically relevant 
association between FSTL5 mutation status and YAP1 protein accumulation that is 
consistent with inactivation of the Hippo tumour suppressor pathway24. Pertinently, 
overexpression of YAP1 was sufficient to confer resistance to XPO1 inhibitors (Fig. 4f and 
Extended Data Fig. 6d, e). Furthermore, chemical (using verteporfin) or genetic (using 
siRNAs targeted at YAP/TEAD2) inhibition of YAP1 transcription factor activity was 
sufficient to confer XPO1 inhibitor sensitivity (Fig. 4g and Extended Data Fig. 6i). 
Activation of AMPK by the cAMP analogue AICAR can inhibit productive YAP1/TEAD 
interactions by phosphorylation of YAP1 Ser94 (ref. 25). AICAR also reversed resistance to 
XPO1 inhibitors, but only in KRAS-mutant cell lines with an intact AMPK response (Fig. 
4g and Extended Data Fig. 6f–h). Thus, FSTL5 is mechanistically coupled to YAP1 pathway 
activation, dictating sensitivity of KRAS-mutant NSCLC cells to chemical inhibition of 
XPO1.
Evaluation of the sensitivity of additional NSCLC lines to XPO1 inhibition identified one 
unexpected KRAS-wild-type responder (H1648) and two unexpected KRAS-mutant non-
responders (HCC515 and Calu1) (Extended Data Fig. 6j). We found that H1648 contains 
genomic amplification of IKKB (a gene encoding IκB kinase β, an inhibitor of IκBα; also 
known as IKBKB) together with a transcription profile indicative of NFκB pathway 
activation (Extended Data Fig. 6k), suggesting sensitivity to XPO1 inhibitors owing to 
KRAS-independent addiction to NFκB signalling. HCC515 and Calu1 were found to 
harbour a LATS1 mutation (LATS1 R904X) and the loss of Merlin (also known as NF2) 
expression, respectively (Extended Data Fig. 6l), with both responding to YAP1 inhibition in 
combination with KPT-330 (Extended Data Fig. 6m). These additional exceptions were 
therefore accounted for by the mechanistic hypothesis.
Collectively, our observations indicate both that addiction to XPO1-dependent nuclear and 
cytoplasmic trafficking is a druggable liability in KRAS-mutant lung cancers and that 
genomics-guided patient selection and patient monitoring will be important if maximum 
benefit is to be achieved from XPO1 inhibitors.
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METHODS
No statistical methods were used to predetermine sample size. The experiments were not 
randomized. The investigators were not blinded to allocation during experiments and 
outcome assessment.
Cell lines and reagents
NSCLC cell lines were established at the NCI and The University of Texas Southwestern 
Medical Center or were obtained from the ATCC. They were maintained in RPMI 1640 
(Gibco), supplemented with 5% heat-inactivated fetal bovine serum (FBS; Atlanta 
Biologicals) and 1% penicillin/streptomycin (Gibco) in a humidified chamber at 5% CO2. 
HBEC30 and HBEC30-KP were maintained in ACL4 (RPMI 1640 supplemented with 0.02 
mg ml−1 insulin, 0.01 mg ml−1 transferrin, 25 nM sodium selenite, 50 nM hydrocortisone, 
10 mM HEPES, 1 ng ml−1 EGF, 0.01 mM ethanolamine, 0.01 mM O-
phosphorylethanolamine, 0.1 nM triiodothyronine, 2 mg ml−1 BSA, 0.5 mM sodium 
pyruvate) with 2% FBS and 1% penicillin/streptomycin. All cell lines were authenticated 
using short tandem repeat (STR) profiling (PowerPlex 1.2, Promega) for at least eight 
different loci and results were compared with reference STR profiles available through the 
ATCC or established by our laboratory. Following authentication, cell-line stocks were 
frozen and maintained in liquid nitrogen until they were used in the reported experiments. 
Polyclonal stable cell lines were established by infecting parental cells with the indicated 
retroviral vector (Extended Data Figs 5h, 6d) or transfecting parental cells with the indicated 
plasmid (Extended Data Fig. 2h), followed by antibiotic selection for 7–14 days. XPO1C528S 
knock-in cell lines were generated by CRISPR/Cas9-induced homologous recombination as 
previously described12. All cell lines were mycoplasma-tested before experiments (iNtRON 
biotechology).
KPT-185 and KPT-330 were provided by Karyopharm Therapeutics. BMS-345541 and 
Verteporfin were purchased from Sigma. Antibodies were purchased from Cell Signaling 
(cPARP 9541, IκBa 4814, YAP1 12395, LATS1 3477, Histone H3 9715, ACC 3676, pACC 
3661, Lamin A/C 4777), Sigma (β-actin A1978, Flag F1804), Abcam (Merlin ab88957) and 
Santa Cruz Biotechnology (XPO1 sc5595 and YAP1 sc101199 for immunofluorescence 
assay). The mutations in the NES of NFKBIA (M45A, L49A, I52A; Extended Data Fig. 4h) 
and the silent mutations in XPO1 (TGACACGGACTCAATTAAC; Extended Data Fig. 2h) 
were generated using the Q5 Site-Directed Mutagenesis Kit (New England Biolabs). All 
siRNAs used for small-scale experiments were obtained from Dharmacon. LONRF1 siRNA 
was used as a negative control siRNA. All siRNA sequences are provided in Supplementary 
Table 8.
siRNA screens and data processing
Two commercial genome-wide siRNA libraries from Ambion (library 1, 21,585 genes) and 
Dharmacon (library 2, 18,175 genes) were purchased in the 96-well plate format. siRNAs 
were dissolved in siRNA buffer (Dharmacon) overnight to a final concentration of 10 μM 
and stored at −80 °C before use. Libraries 1 and 2 are a mix of 3 and 4 individual siRNA 
oligo-nucleotides per gene, respectively. Transfection protocols were optimized for each cell 
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line as previously described7. For reverse transfection, 3 μl of each siRNA pool (10 μM) was 
transferred to serum-free RPMI (95 μl per well) in empty 96-well assay plates (Costar). 30 
μl of this siRNA solution was transferred to an empty 96-well optical assay plate (BioMek), 
incubated for 5 min, then mixed with 10 μl transfection reagent solution (0.13 μl RNAi Max 
(Invitrogen) in 10 μl serum-free RPMI), and incubated for 15 min. Cells were collected and 
diluted in parallel, then added to the siRNA–lipid mix and incubated for 96 h. All screens 
were performed using biological triplicates. CellTiter-Glo (Promega) assays were performed 
using 15 μl reagent per well followed by a 10 min incubation before quantitation of 
luminescence with an Envision plate reader (PerkinElmer). siUBB (siRNA against UBB, 
ubiquitin B; Dharmacon) was used as a positive control for toxicity for all cell lines. Screen 
data were row- and column-median-normalized and log2-transformed. Mean values from 
triplicates were used to calculate batch-centred Z scores using siMacro26.
Hierarchical clustering by UPGMA was performed using the ‘stats’ package in R, based on 
Euclidean distance using the ‘complete’ agglomeration method.
Functional GSEA analysis
Within each individual cell line, minimum gene-level Z scores were binned according to the 
following rules:
GSEA was then performed with the signal-to-noise ranking metric to determine gene sets 
that contained significantly lower Z scores in KRAS-mutant compared to the KRAS wild-
type cells. A plot of the running sum (Fig. 1c) and the resulting signal-to-noise ratio at each 
point in the ranked list was constructed in R. The top gene sets preferentially ‘lower’ (that is, 
containing genes corresponding to siRNA pools with low (toxic) Z scores) in the KRAS-
mutant cell lines were defined as those that had a P <1×10−16 and FDR <0.2 (Extended Data 
Fig. 2b). We performed a leading-edge analysis using the Broad GSEA software to identify 
genes enriched across multiple significant gene sets (Extended Data Fig. 2c).
Gene expression and data processing
Raw Illumina HumanWG-6 v3.0 Expression BeadChip files for the NSCLC cell lines used 
in this study are available from the Gene Expression Omnibus using accession number 
GSE32036. Data were background-corrected using the ‘MBCB’ package in R, which 
provides a model-based background correction method similar to an RMA correction with 
affymetrix arrays. Data were then quantile-normalized to produce equivalent expression 
distributions amongst cell lines.
To evaluate the distribution of expression variation within the NSCLC panel, standard 
deviations were calculated for expression of each of 25,235 genes (Illumina HumanWG-6 
v3.0) across the full panel of 106 NSCLC lines, the 37 KRAS-mutant NSCLC lines, and the 
69 KRAS-wild-type NSCLC lines (Supplementary Table 1, 2 and refs 27–30). Kernel 
density estimates were determined using the ‘stats’ package in R.
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To examine the gene regulatory pathways affected by XPO1 inhibition, cells were exposed 
to either DMSO or 1 μM KPT-185 for 12 h. Total mRNA was isolated and gene expression 
profiling was performed using Illumina HT12v4 BeadChip. Expression values were 
extracted using GenomeStudio 2010.2. The raw values were background-corrected, quantile-
normalized, log2-transformed and subjected to GSEA.
To examine the transcriptional response to LATS and FSTL5 depletion, cells were first 
transfected with siLATS1/2 and siFSTL5. 72 h post-transfection, cells were processed for 
gene expression profiling as described above. The raw intensities were background-
corrected, quantile-normalized and log2-transformed. Genes with log2 expression values ≤4 
across the samples were excluded from further analysis.
For targeted gene expression analysis, total cellular RNA was isolated using RNeasy 
miniprep Kit (Qiagen). cDNA was then synthesized using High-Capacity RNA-to-cDNA 
kits (Applied Biosystems) and subjected to quantitative PCR (qPCR) with TaqMan gene 
expression assay kits (Applied Biosystems).
Unpaired t-tests and two-sample Kolmogorov–Smirnov tests were performed using the R 
‘stats’ package.
Affinity-propagation-based similarity clustering analysis
Clustering analysis was performed with the affinity propagation clustering (APC) algorithm 
using the ‘apcluster’ package in R. APC is a deterministic clustering method that identifies 
the number of clusters and cluster ‘exemplars’ (that is, the cluster centroid or the data point 
that is the best representative of all the other data points within that cluster) entirely from the 
data6, giving it an advantage over non-deterministic methods subject to a biased randomized 
initialization step, such as hierarichial clustering or methods in which the number of clusters 
has to be pre-specified, such as k-means clustering.
APC performs clustering by passing messages between the data points. It takes as input a 
square matrix representing pairwise similarity measures between all data points. The 
algorithm views each data point as a node in a network and is initialized by connecting all 
the nodes together, where edges between nodes are proportional to Euclidean distance. The 
algorithm then iteratively transmits messages along the edges, pruning edges with each 
iteration until a set of clusters and exemplars emerges.
Two real-valued messages are passed between nodes. The ‘responsibility’ message computes 
how well-suited point i is to choose point k as an exemplar, given all the other candidate 
exemplars, k′, and is updated by:
The availability message, a(i,k), computes how appropriate it is for point i to select point k 
as an exemplar, taking into account all the other points for which k is an exemplar, i′, and is 
given by:
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In the above equation, a(i, k) is set to the self-responsibility, r(k, k), plus the sum of the 
positive responsibilities candidate k receives from other points. The entire sum is 
thresholded at 0, with a negative availability indicating that it is inappropriate for point i to 
choose point k as an exemplar so the tie is severed. The self-availability, a(k, k), reflects the 
accumulated evidence that point k is an exemplar and is updated with the following rule, 
which reflects the evidence that k is an exemplar based on the positive responsibilities sent 
to k from all points, and is updated by:
In the first iteration, all points are considered equally likely to be candidate exemplars, and 
a(i, k) is set to 0 and s(i, k) is set to the input similarity measure between points i and k. The 
above rules are then iteratively updated until a clear, stable set of clusters and exemplars 
emerges.
In our implementation, we first used the algorithm to identify an initial set of exemplars and 
clusters from the data matrix. The exemplars were then clustered together and this procedure 
was repeated until no more clusters emerged, identifying a hierarchical structure of clusters. 
Networks were drawn with cytoscape31 in the following manner. All members of the 
primary clusters are interconnected, and edge lengths are drawn to be proportional to 
Euclidean distances. Edge lengths between exemplars that cluster together are also drawn to 
be proportional to Euclidean distances. The entire map was rendered in a two-dimensional 
display using a cytoscape built-in spring-embedded algorithm.
To cluster 106 NSCLC cell lines with defined KRAS status by similar expression profiles 
(Fig. 1a, Extended Data Fig. 1a), we first reduced the panel of genes to those that were 
expressed at a log2-normalized expression value of 6 in at least one cell line and those that 
were present in the top 20% of the most highly variant genes; this resulted in a panel of 
3,101 detectable and variable genes.
Retrospective analysis of genome-wide synthetic-lethal shRNA screen data
Extended Data Fig. 2f was generated using genome-wide synthetic-lethal shRNA screening 
data3. The shRNA screen was performed in an isogenic pair of KRAS wild-type and 
KRASG12D colorectal cancer cell lines with 6 pools of ′13,000 shRNAs/pool targeting 
32,293 human transcripts. log2 fold changes in relative abundance of each shRNA depleted 
over time were analysed for each sample. Those with a fold-depletion equal or less than 0 in 
any sample were then compared between samples (KRAS-mutant versus KRAS wild-type) 
using the non-parametric two-sample Kolmogorov–Smirnov test.
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Cell viability and cytotoxicity assay
For dose–response curves, cells were plated at 50% density in 96-well assay plates. On the 
following day, serially diluted compounds or vehicle alone were added to the culture media. 
Cell viability was measured using CellTiter-Glo (Promega) 72 h post-treatment. For dose–
response analysis of XPO1 inhibitors combined with either siRNAs or chemical inhibitors 
(Extended Data Figs 4g, k, 5f, g, 6i), cell viability was normalized to the indicated matching 
controls. AUCs were computed by the trapezoidal method using GraphPad software. 
Caspase enzymatic activity was analysed using Caspase-Glo 3/7 (Promega) after compound 
treatment according to manufacturer’s instructions. The raw luminescence values were 
divided by the average luminescence values of matching controls (Figs 2b, 3e). To examine 
the cytotoxic effect of compounds on post-confluent cells, NSCLC cells were cultured to 
confluence in 6-well plates, exposed to compounds as indicated, then fixed in 100% cold 
methanol for 10 min and stained with 0.5% crystal violet for 30 min at room temperature. To 
examine tolerance to ectopic expression of nuclear IκBα, test plasmid DNA (pEGFP-C3-
IκBα-NES-Mut) and control plasmid DNA (pEGFP-C3) were transfected into H2882 cells 
and H2009 cells in 12-well plates. 48 h and 72 h after transfection, cells were fixed and the 
GFP/DAPI ratio was examined using images taken with a Zeiss Plan 20×/0.30 PH1 objective 
on a Zeiss Axioplan 2E microscope. The following formula was used:
Proliferation rate measurement of NSCLC lines
Cells were counted at seeding, allowed to grow to a confluence of 80–90% and then 
harvested and the total cell number was determined. Population-doubling time was 
calculated using the following formula: number of hours from seeding to collection/((logn(t) 
− logn(t0))/log2). n(t) is the number of cells at time of passage and n(t0) is the number of cells 
seeded at previous passage32.
Targeted siRNA and plasmid DNA transfection
For transfection in 96-well plates, 1 μl siRNA (10 μM) in 30 μl of serum-free RPMI was 
mixed with 0.4 μl of RNAi Max (Invitrogen) in 10 μl of serum-free RPMI. Following a 15 
min incubation, the siRNA–lipid mix was transferred to empty 96-well assay plates followed 
by delivery of single cell suspensions (100 μl per well). For transfection in 6-well plates, 10 
μl siRNA (10 μM) in 250 μl of serum-free RPMI was mixed with 7 μl RNAi Max in 250 μl 
of serum-free RPMI and were delivered to plates followed by delivery of single-cell 
suspensions (2 ml per well). For plasmid DNA transfection in 12-well plates, 0.5 μg of 
plasmid DNA in 25 μl of serum-free media was mixed with 1.5 μl Fugene 6 (Promega) in 25 
μl of serum-free media. After a 15-min incubation, suspended cells (1 ml per well) were 
added to the plate with DNA–Fugene 6 complexes. For plasmid DNA transfection in 60-mm 
dishes, cells were pre-plated and 2 μg DNA/6 μl Fugene 6 complexes in 100 μl of serum-free 
media were delivered to the cells the next day.
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NFκB transcriptional activity reporter assay
Cells were reverse-transfected in 96-well microtitre plates with a reporter plasmid 
(pGL4.32[luc2p/NFκB-RE/Hygro], Promega) expressing firefly luciferase under the control 
of a multimerized NFκB-responsive element together with the pRL-SV40 Renilla luciferase 
control reporter plasmid at a ratio of 9:1. 24 h post-transfection, cells were exposed to 
compounds as indicated for 24 h and then treated with 4 ng ml−1 TNF for 6 h. Luciferase 
activities were measured using the Dual luciferase reporter system (Promega) according to 
manufacturer’s instructions.
Mouse xenografts
NOD/SCID female mice at 4–9 weeks of age were injected subcutaneously with H2882 (3 
×105), H2009 (5 ×105), and H460 (2.5 ×105) cells. When tumours reached 100 mm3 or 
larger, mice were randomly assigned to three cohorts and orally treated with vehicle (0.6% 
(w/v) PVP K-29/32 and 0.6% (w/v) Pluronic F-68), 3 mg kg−1 KPT-330, or 10 mg kg−1 
KPT-330 three times a week by oral gavage. Tumour volume was monitored with digital 
callipers using the following formula: Width2 × Length/2. Nutri-Cal (Tomlyn) was provided 
to mice throughout the experiment as a nutritional supplement. Mice were killed when 
xenografts reached 2 cm3. The number of mice per cohort was as follows: for H2882 
xenografts, vehicle, n = 7; 3 mg kg−1, n = 7; 10 mg kg−1, n = 6; for H2009 xenografts, 
vehicle, n = 8; 3 mg kg−1, n = 8; 10 mg kg−1, n = 9; for H460 xenografts, vehicle, n = 5, 3 
mg kg−1, n = 4, 10 mg kg−1, n = 5.
For bioanalysis of KPT-330 in mouse plasma, plasma samples were collected by cardiac 
puncture from mice (n = 4 per group), processed with three volumes of methanol containing 
internal standard (propranolol) and then centrifuged at 1,000g for 10 min. The supernatant 
was analysed by LC–MS/MS using an Agilent 6410 mass spectrometer coupled with an 
Agilent 1200 HPLC and a CTC PAL chilled autosampler, all controlled by MassHunter 
software (Agilent). After separation on a C18 reverse-phase high-performance liquid 
chromatography column (Agilent), using an acetonitrile-water gradient system, peaks were 
analysed by mass spectrometry using ESI ionization in MRM mode. All plasma samples 
were compared to a calibration curve prepared in mouse blank plasma.
KrasLSL-G12D;p53fl/fl GEM model
KrasLSL-G12D;p53fl/fl mice were infected with 2.5 ×107 PFU of Ad-Cre (University of Iowa, 
Gene Transfer Vector Core) intratracheally at 7–8 weeks of age as previously described33. 
Eight to ten weeks after the injection, tumour development was monitored by magnetic 
resonance imaging (MRI) before treatment. Mice with equivalent tumour burden were 
randomly assigned to two cohorts and orally treated with either vehicle (0.6% (w/v) PVP 
K-29/32 and 0.6% (w/v) Pluronic F-68; n = 3) or 10 mg kg−1 KPT-330 (n = 4) three times a 
week by oral gavage. Outlier animals presenting with exceptionally high tumour burden 
were treated with 10 mg kg−1 KPT-330 five times a week by oral gavage. After the three 
weeks of treatment, lungs were imaged by MRI, then collected, fixed with 10% formalin, 
paraffin-embedded, and H&E stained. The stained lung-tissue specimens were scanned in 
Hamamatsu Nanozoomer 2.0HT for visualization and evaluation. Tumour burden was 
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determined on the largest lobe and calculated as the tumour area divided by lung area. Area 
of interest was quantified using ImageJ software.
All magnetic resonance images were obtained using a 7T small-animal MRI scanner 
(Agilent (Varian), Inc.) equipped with a 40 mm Millipede RF coil (ExtendMR LLC, 
Milpitas, CA). All MRI acquisitions were gated using both cardiac and respiratory 
triggering. The images were recorded on the transverse plane, with the major parameters as 
follows: repetition time (TR), 200; echo time (TE), 1.834 ms; flip angle (FA), 45°; number 
of average, 8; field of view (FOV), 32 ×32 mm2; matrix size, 256 × 256; slice number, 17; 
slice thickness, 1 mm without any gap.
Patient-derived xenografts
Human KRASG12D T2aN0Mx stage lung adenocarcinoma tissue was obtained from a 40-
year-old patient with lung cancer and directly implanted into the liver capsule of a NOD/
SCID mouse. Written informed consent was obtained from the patient. Tissue procurement 
for the generation of patient-derived xenografts was approved by the Institutional Review 
Boards of UTSW. The mouse was killed 18 weeks later and the engrafted tumour was 
collected, divided, frozen in 10% DMSO/90% FBS and stored at −80 °C until being re-
implanted subcutaneously to another NOD/SCID mouse in both flanks. When the tumours 
reached ~10 mm in length they were resected, evenly divided into 19 pieces and re-
implanted subcutaneously to 10-week-old NOD/SCID female mice. Mice harbouring 
palpable engrafted tumours (58–101 mm3) were randomly assigned to receive either carrier 
(0.6% (w/v) PVP K-29/32 and 0.6% (w/v) Pluronic F-68; n = 6) or 10 mg kg−1 KPT-330 (n 
= 6) three times a week. Tumour volume was monitored with digital callipers using the 
following formula: tumour volume = width2 ×length/2.
All mouse studies were performed according to the guidelines of the UT Southwestern 
Institutional Animal Care and Use Committee.
Immunofluorescence and immunohistochemistry
For immunofluorescence-based imaging, cells were fixed with 3.7% formaldehyde (Fisher 
Scientific), perme-abilized with 0.1% Triton X-100, blocked with PBST (PBS containing 
1% bovine serum albumin and 0.1% Tween-20) and incubated with antibodies in PBST 
against the indicated proteins. Representative images were captured with a PCO: sCMOS 
5.5 camera on a Zeiss Axioplan 2E microscope.
For immunohistochemistry-based protein expression analysis, paraffin- embedded mouse 
tumour samples were deparaffinized, subjected to heat-induced antigen retrieval in 10 mM 
sodium citrate buffer, blocked using 3% peroxidase (Sigma), Avidin/Biotin blocking Kit 
(Vector laboratories), and M.O.M. Kit (Vector laboratories) and incubated with anti-IκBα 
antibody (Cell Signaling, 1:50) and then biotinylated secondary antibody followed by ABC 
reagent (Vector Laboratories). The samples were stained using immPACT DAB (Vector 
Laboratories) and counter stained using Mayer’s haematoxylin solution (Sigma).
In tissue microarrays with patient-derived lung tumour samples, immunohistochemistry 
reactions were performed using a Leica Bond Max automated stainer (Leica Biosystems, 
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Nussloch GmbH). In summary, the NSCLC TMA slides were deparaffinized and hydrated in 
the Leica Bond autostainer. The primary antibodies used were YAP1 (rabbit monoclonal, 
clone D8H1X, Cell Signaling Technology, 14074, 1:100). Antigen retrieval was performed 
using Bond Epitope Retrieval Solution No. 1 (AR9961, Leica Biosystems; equivalent to 
citrate buffer pH 6.0). The immunohistochemistry reaction was detected using the Bond 
Polymer Refine Detection (Ref # DS98000, Leica Biosystems) with diaminobenzidine as 
chromogen for the visualization of the staining. The slides were counterstained with 
haematoxylin (Leica Biosystems). Formalin-fixed, paraffin-embedded (FFPE) human breast 
and colon adenocarcinomas were used as positive controls. Non-primary antibody control 
was also used as an additional control. All TMA slides were stained for YAP1 at the same 
time with the controls and cell line samples. The stained slides were scanned in an Aperio 
AT Turbo digital pathology system (Leica Biosystems) for visualization and evaluation. 
Immunohistochemistry quality control and scoring were performed by two pathologists (P.V. 
and J.R.C.). The immunohistochemistry scoring system employed was H-score, which 
evaluated intensity (0 to 3) and percentage of positive tumour cells (0 to 100), with a final 
scoring ranging from 0 to 300.
The tissue microarrays used in this study comprised 37 surgically resected lung 
adenocarcinoma tumours. All specimens were collected from the lung cancer tissue bank at 
The University of Texas M. D. Anderson Cancer Center, which is approved by the M. D. 
Anderson Institutional Review Board. After histological examination, tissue microarrays 
were constructed using three 1-mm-diameter cores per tumour. Tissue microarrays were 
prepared with a semi-automatic tissue arrayer (Veridiam Tissue Arrayer Model VTA-100, 
Veridiam) using 1 mm diameter cores in triplicate for tumours, as described previously34. 
Histological sections that were 4 μm in thickness were then prepared for the subsequent 
immunohistochemical analysis. Clinical and pathological information was obtained for all 
patients (Supplementary Table 7). Pathological tumour-node-metastasis stage had been 
determined for lung cancers at the time of primary tumour surgery.
Whole-exome deep sequencing and targeted sanger sequencing
Genomic DNA from NSCLC lines and patient-matched B-cell lines was isolated using 
DNeasy Blood and Tissue Kits (QIAGEN). Exonic DNA was captured using SureSelect 
38MB All Exon Kit (Agilent) following manufacturer’s protocol and sequenced using 
HySeq 2000 (Illumina) using a paired-end sequencing protocol with reads aligned to the 
NCBI human genome by Bowtie 0.12.5 as previously described7,35, allowing for up to 2 
mismatches per read. Single-nucleotide variants (SNV) were discovered from within the 
uniquely aligned reads, with at least one mismatch with a Phred quality score greater than 20 
and coverage greater than 6 by non-redundant reads. Somatic SNVs were identified by 
requiring coverage on the variant site by the wild-type allele to be greater than 6 and to be 0 
by the mutant allele. A series of filters was used to screen out probable germline mutations 
from somatic mutations identified in NSCLC cell lines without a matched normal B-cell 
line. They are as follows: (i) germline variants that were found in the matched dataset were 
removed; (ii) variants that were found to be present in dbSNP (http://www.ncbi.nlm.nih.gov/
SNP/) but not in COSMIC (http://cancer.sanger.ac.uk/cosmic) were removed; (iii) silent, 
intergenic and untranslated region variants were removed; (iv) variants that were found at a 
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frequency ≥8% in the thousand-genome project were removed; (v) variants in genes that 
were mutated ≥62 times at any site across the panel were removed; and (vi) variants that 
were mutated at the same amino acid position in more than 9 cell lines were removed 
(variants that were found to be ‘hotspots’ in the matched dataset were, however, rescued).
For targeted detection of mutations in FSTL5, genomic DNA was extracted from patient-
derived human lung tumour samples and from matched normal tissue. Exons 2–16 were 
amplified by PCR with HotStarTqa Master Mix kit (Qiagen), purified using USB ExoSAP-
IT (Affymetrix) and Sanger-sequenced. For exons that exhibited mixed chromatograms, 
PCR products were cloned using TOPO TA cloning kit (Invitrogen) and the resulting clones 
were individually sequenced.
Bicluster analysis
We converted the mutation table to a binary-presence call table in which ‘1’ indicated the 
presence of a mutation in a cell line and ‘0’ indicated the wild type. We created a 
biclustering script that searches for every possible permutation of rows (that is, genes) and 
columns (cell lines) to identify the biggest blocks of 1s in the dataset. In other words, we 
search for the largest number of mutations that are shared by the largest number of cell lines. 
We then identified the bicluster that identified mutations that were shared by KRAS-mutant/
XPO1-inhibitor-resistant lines that were not present in the KRAS-mutant/XPO1-inhibitor-
sensitive lines. This bicluster contained the single gene FSTL5.
Retrospective analysis of shRNA enrichment in HCC
Extended Data Figure 5e was generated from an oncogenomics-based in vivo RNAi 
screening result19 (Supplementary Table 3). Shown are 36 shRNAs enriched at least 2.5-fold 
over the predicted representation during HCC tumour development.
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Extended Data
Extended Data Figure 1. Two-dimensional APC projection of 106 NSCLC lines based on whole-
genome mRNA expression variation
High-resolution, annotated version of Fig. 1a.
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Extended Data Figure 2. Synthetic-lethal genetic interactions in KRAS-mutant NSCLC cells
a, Distribution of the variation in mRNA expression among KRAS-mutant lines (red curve, 
n = 37), KRAS-wild-type lines (blue curve, n = 69) and all NSCLC lines (green curve). b, 
Top-ranked gene sets (FDR <0.2, Kolmogorov–Smirnov P <1 ×10−16) returned by 
functional GSEA. c, Genes present in leading edge gene representation among the gene sets 
in b. Known components of nuclear transport machinery (indicated in d) are labelled in blue. 
d, Biological process representation of the leading-edge synthetic-lethal gene-depletion 
targets. e, Cumulative distributions of the viability Z-scores for siRNA pools, targeting genes 
in d, among KRAS-mutant versus KRAS-wild-type cell lines. Kolmogorov–Smirnov test P 
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value is indicated. f, Cumulative distributions of log2 difference scores for depletion of 
shRNAs in KRAS-mutant versus KRAS-wild-type cells. Red, shRNAs targeting genes 
encoding nuclear transport machinery from e; black, all other shRNAs. Kolmogorov–
Smirnov test P value is indicated. Data obtained from a previous study3. g, Cell viability 
after UBB depletion (a broadly toxic siRNA target that serves as a positive transfection 
control) in KRAS-mutant versus wild-type lines. Unpaired t-test was used for the 
comparison. h, Rescue of XPO1 siRNA toxicity by ectopic expression of a mutant XPO1 
cDNA designed to be resistant to XPO1 siRNA number 4. Lamin A/C is shown as a loading 
control.
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Extended Data Figure 3. Selective sensitivity of KRAS-mutant NSCLC cells to chemical 
inhibition of the nuclear transport receptor XPO1
a, Structures of SINE compounds (XPO1 inhibitors), KPT-185 and KPT-330. b, Enrichment 
of short doubling times in KRAS-mutant versus wild-type NSCLC lines. Box plots indicate 
median and IQR. Unpaired t-test was used for the comparison. c, The 8-point dose–response 
viability curves for the indicated panel of NSCLC lines following a 72-h exposure to 
KPT-185. Mean ± s.d. (n = 3) is shown. d, Correlation of sensitivity to the XPO1 inhibitors 
KPT-330 and KPT-185. AUCs from c and Fig. 2a. Red, KRAS mutant; blue, KRAS wild 
type. Pearson correlation P value is indicated. e, Response of KRAS-mutant versus KRAS-
wild-type cohorts to XPO1 inhibitors. Box plots indicate median values and IQR, an 
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unpaired t-test was used for the comparison. f, Scatter plot of cell-line doubling time versus 
KPT-185 sensitivity. Pearson correlation P value is indicated. g, Sequencing chromatogram 
of XPO1 genomic DNA of genome-edited cells. The C528S substitution was induced by 
CRISPR/Cas9-induced homologous recombination. Three synonymous mutations were 
simultaneously introduced near the PAM site (underlined) in order to prevent re-cutting of 
the recombined DNA. h, Selective sensitivity of KRAS-mutant lines to KPT-330 at doses 
over 400% higher than bioactive in vivo concentrations. Post-confluent cells were exposed 
to KPT-330 for 5 days. i, Response of KRASG12V-expressing lung epithelia (HBEC30KP), 
versus wild-type parental epithelia (HBEC30), to KPT-185 and KPT-330. Left, mean ± s.d., 
n = 3; right, monolayer assay is as in h. j, Cytotoxic effect of 2 μM KPT-330 on the 
indicated NRAS-mutant cell lines. Monolayer assay is as in h. k, Lung tumour burden pre- 
and post-treatment as indicated by magnetic resonance images. Two mice presenting with 
exceptionally high initial tumour burden were treated with 10 mg kg−1 KPT-330 five times 
per week. Lungs were imaged with serial transverse magnetic resonance sections on 
treatment day 0 and again on day 21.
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Extended Data Figure 4. Selective addiction to NFκB activity specifies sensitivity to XPO1 
inhibition
a, Top five gene sets that significantly discriminate XPO1-inhibitor-sensitive lines from 
XPO1-inhibitor-resistant lines. NFκB target gene sets are indicated in blue. b, Top 50 
differentially expressed genes ranked by signal-to-noise (S2N) ratio. Known NFκB targets 
are indicated in red (16/133; hypergeometric P <1 ×10−16). c, Top 3 gene sets that are 
downregulated by a 12-h exposure to an XPO1 inhibitor. NFκB target gene sets are indicated 
in blue. d, Enrichment plot of NFκB target genes (KPT-185-treated versus DMSO-treated). 
e, Evidence for attenuated NFκB signalling in XPO1-inhibitor-resistant NRAS-mutant cell 
lines. Empirical cumulative distributions of NFκB target gene expression (from b) are 
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shown for NRAS-mutant cell lines versus KRAS-mutant cell lines as indicated. Yellow, 
NRAS-mutant/XPO1-inhibitor-resistant lines (H2087, H1299 and HCC1195, shown in 
Extended Data Fig. 3j); red, KRAS-mutant/XPO1-inhibitor-sensitive line (shown in Figs 2, 
3). Yellow versus red, P < 0.01 using Kolmogorov–Smirnov test. f, Immunoblot of IκBα 48 
h post-transfection of siNFKBIA/siNFKBIB (targeting genes that express IκBα/IκBβ) for 
confirmation of target depletion. Histone H3 is shown as a loading control. g, IκB-dependent 
sensitivity to KPT-185. Cells were exposed to the indicated concentrations of XPO1 
inhibitors for 72 h 24 h post-transfection with the indicated siRNA. Mean and range (n = 2). 
h, Intolerance to ectopic nuclear accumulation of IκBα in XPO1-inhibitor-sensitive cells. 
Left, y axis indicates fold change in the percentage of GFP-positive nuclei of GFP-IκB-
NES-mutant-positive cells normalized to GFP-empty-vector-positive cells. Bars indicate 
mean ± s.d. for three independent experiments (*P <0.05, Unpaired t-test). Right, 293T cells 
transfected with the indicated plasmids to confirm plasmid transfection efficiency and 
localization of ectopically expressed proteins. Cells were fixed and photographed 48 h post-
transfection. i, Positive correlation between sensitivity to KPT-185 and BMS-345541 (P 
<0.01, Pearson correlation). Dose–response curves of a panel of NSCLC lines following a 
72-h exposure to BMS-345541. Mean ± s.d. (n = 3). AUCs of KPT-185 were determined 
from Extended Data Fig. 3c. Red labels, KRAS mutant/XPO1-inhibitor sensitive; green 
labels, KRAS mutant/XPO1-inhibitor resistant; blue labels, KRAS wild type. j, Dose–
response curves of a panel of NSCLC lines following a 72-h exposure to Trametinib. Mean 
and range (n = 2). Label colours as in i. k, Dose–response curves of a panel of NSCLC lines 
following a 72-h exposure to KPT-185 combined with the indicated concentrations of 
Trametinib. Mean and range (n = 2). l, Subcellular localization of IκBα in the presence of 1 
μM KPT-185. Cells were exposed to KPT-185 for 24 h. Label colours are as in i.
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Extended Data Figure 5. Concurrent mutations in FSTL5 are associated with intrinsic resistance 
of KRAS-mutant lines to XPO1 inhibitor
a, Eight-point dose–response viability curves for H2122 and H2030 following a 72-h 
exposure to KPT-185. Mean ± s.d. (n = 3). Data are overlaid with responses of the indicated 
lines from Extended Data Fig. 3c for comparison. b, KPT-185 dose–response curves. Mean 
± s.d. (n = 3). c, FSTL5 Sanger-sequencing chromatograms of detected FSTL5 variants in 
the indicated cell lines. d, Map of somatic alterations in FSTL5 detected in all cancers 
(TCGA), lung adenocarcinoma (TCGA), lung squamous (TCGA), NSCLC cell lines (this 
study), and human lung tumour samples, 1805 and 1930 (this study). e, Tumour suppressor 
genes identified in an oncogenomics-based in vivo RNAi screen19. Among the genes 
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targeted by 36 shRNAs overrepresented during HCC tumour development, Fstl5 was the 
third ranked gene suppressed by >1 enriched shRNA. The y axis indicates number of 
shRNAs per gene among the 36 enriched shRNAs. The x axis indicates shRNA specific 
reads over a total 2,307 sequence reads. f, g, KPT-185 dose–response of cells transfected 
with the indicated siRNAs as in Extended Data Fig. 4g. f shows KRAS-mutant/FSTL5-wild-
type lines, g shows KRAS-mutant/FSTL5 mutant lines. Mean and range (n = 2). h, Relative 
ectopic expression of FSTL5 mRNA. Cells were infected with retrovirus carrying the 
indicated plasmids. Following a 7-day puromycin selection, cells were collected for qPCR. 
Mean and range (n = 2).
Extended Data Figure 6. Concurrent mutations in FSTL5 are mechanistically coupled to YAP1 
activation
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a, Expression of FSTL5 mRNA (left) and YAP1 protein (right) following transfection with 
the indicated siRNAs targeting FSTL5. Cells were collected 72 h post-transfection for 
parallel qPCR and immunoblotting. Mean and range (n = 2). b, Intersection of the FSTL5-
dependent and LATS-dependent gene expression programs in KRAS-mutant/XPO1-
inhibitor-sensitive NSCLC lines. To evaluate the enrichment of YAP-responsive genes 
within the FSTL5-dependent gene expression network, quantitative whole-genome transcript 
arrays were prepared with mRNA isolated from the indicated cell lines treated with the 
indicated siRNAs 72 h post-transfection. LATS1/2 depletion was used to activate YAP-
dependent gene expression. All arrays were normalized to corresponding control siRNA-
treated samples. Euler plots indicate genes up- or downregulated at least twofold in response 
to siFSTL5, siLATS or both; hypergeometric P values are indicated. c, YAP1 fluorescence 
micrographs and representative YAP1 immunohistochemistry. H2009 and H2030 cell lines 
were used as a negative and positive control for YAP1 staining, respectively. d, Stably 
overexpressed YAP1 in KRAS-mutant/XPO1-inhibitor-sensitive lines. Cells were infected 
with the indicated retroviral vector, selected with hygromycin and then collected for 
immunoblotting. e, Induction of XPO1-inhibitor resistance by YAP1 overexpression. 
Proliferating cells stably expressing indicated plasmids were exposed to XPO1 inhibitors for 
3 days. Mean ± range (n = 2). f, Immunoblot of the indicated proteins in KRAS-mutant/
XPO1-inhibitor-resistant lines following a 24-h exposure to 1 mM AICAR. AICAR resulted 
in accumulation of phospho-acetyl-CoA-carboxlyase (pACC), an indicator of AMPK 
activation in all the lines tested except A549. A549 is known to be non-responsive to AICAR 
owing to the absence of LKB1 (also known as STK11) expression7. g, Subcellular 
localization of YAP1 in response to 0.5 or 1 mM AICAR. Cells were exposed to AICAR for 
24 h. Cytoplasmic accumulation of YAP1 was observed in response to AICAR exposure in 
H2030, but not in A549. h, Resistance of KRAS-wild-type lines to KPT-330 in combination 
with AICAR. Post-confluent cells were exposed to the indicated compounds for 3 days. i, 
Induction of XPO1 inhibitor-sensitivity by YAP1 and TEAD2 depletion. 48 h post-
transfection with the indicated siRNAs, cells were exposed to the indicated concentrations of 
XPO1 inhibitors for 3 days. Mean and range (n = 2). j, Cytotoxic effect of 2 μM KPT-330 on 
indicated cell lines. Post-confluent cells were exposed to KPT-330 for 5 days. Red labels, 
KRAS-mutant/XPO1-inhibitor-sensitive; green labels, KRAS-mutant/XPO1-inhibitor-
resistant; blue labels, KRAS wild type. k, Evidence for NFκB pathway activation in H1648 
cells. Empirical cumulative distributions of NFκB target gene expression (from Extended 
Data Fig. 4b) are shown for H1648 versus KRAS-wild-type cell lines as indicated. Blue, 
KRAS-wild-type/XPO1-inhibitor-resistant lines (H2882, HCC15, H1395, H1993 and 
HCC95 shown in Figs 2 and 3); yellow, KRAS-wild-type/XPO1-inhibitor-sensitive line 
H1648 (shown in j). Cancer Cell Line Encyclopedia data indicates that H1648 harbours 
genomic amplification of IKBKB. Blue versus yellow, P <0.01, Kolmogorov–Smirnov test. 
l, Merlin expression is absent in Calu1 cells. m, Cytotoxic effect of the indicated compounds 
on the indicated cell lines. Post-confluent cells were treated as in h. HCC515 harbours a 
somatic mutation in LATS1.
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Figure 1. Synthetic-lethal genetic interactions in KRAS-mutant NSCLC cells
a, Two-dimensional APC projection of 106 NSCLC lines based on whole-genome variation 
in mRNA expression. Nodes represent cell lines and edges represent the Euclidean distance 
between cell lines. Red nodes, KRAS mutant (n = 37); blue nodes, KRAS wild type (n = 
69). Cell lines subjected to whole-genome siRNA toxicity screening are highlighted in 
green. b, Binned Z-score distributions of selectively toxic gene depletions across the 
indicated cell lines. Cell lines (in columns; red label, KRAS mutant; black label, KRAS wild 
type) and siRNA target genes (rows) are clustered by two-way unsupervised unweighted pair 
group method with arithmetic mean (UPGMA). c, The reactome NEP NS2 interacts with the 
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cellular export machinery. Empirical cumulative siRNA score distribution for a top-ranked 
KRAS-mutant-enriched gene set. S2N, signal-to-noise ratio. d, Differences in cell viability 
following XPO1 depletion with XPO1 siRNA (siXPO1) in KRAS-mutant versus KRAS-
wild-type (WT) cell lines. Box plots indicate median and interquartile range (IQR). 
Unpaired t-test, P = 0.0359.
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Figure 2. Selective sensitivity of KRAS-mutant NSCLC cells to chemical inhibition of the nuclear 
transport receptor XPO1
a, Dose–response curves for a panel of NSCLC lines following a 72-h exposure to KPT-330. 
Data are mean ± s.d. (n = 3). b, Induction of Caspase 3/7 activity in KRAS-mutant lines by 
KPT-185. Bars indicate mean and range of data (n = 2). c, Accumulation of the cell death 
marker cleaved PARP (cPARP) in KRAS-mutant lines following exposure to 1 μM 
KPT-185. β-actin is shown as a loading control. d, Stationary-phase cell populations 
exposed to KPT-330 for 6 d (crystal violet). e, Rescue of XPO1 inhibitor toxicity by gene 
editing. Dose–response curves are as in a. Mean and range (n = 2). Immunoblots are as in c. 
f, g, Fold change in tumour volume in indicated xenografts upon XPO1 inhibition. *P <0.05, 
**P <0.01, Unpaired t-test, mean ± s.d. h, Representative lung magnetic resonance image of 
KrasLSL-G12D;p53fl/fl mouse is shown before and after treatment for each cohort. Post-
treatment haematoxylin and eosin (H&E)-stained left lung lobe is shown. Tumour burden 
was calculated as the tumour area divided by lung area. Unpaired t-test, P = 0.0263; scale 
bars, 10 mm (left 4) and 5mm (right 2).
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Figure 3. Selective addiction to NFκB activity specifies sensitivity to XPO1 inhibition
a, GSEA gene set, Hinata NFκB targets keratinocyte up. NFκB transcriptional target 
enrichment plot (XPO1-inhibitor-sensitive versus XPO1-inhibitor-resistant). b, Time-
dependent nuclear accumulation of IκBα in response to 1 μM KPT-185. Scale bars, 20 μm. 
c, Time-dependent inhibition of NFκB target gene expression in response to 1 μM KPT-185. 
Mean and range (n = 2). d, Rescue of NFκB transcriptional activity by gene editing. 
Normalized luminescence-based NFκB reporter activity is shown. Mean + s.d. (n = 3). e, 
IκB-dependent induction of apoptosis by XPO1 inhibitors. Cells were transfected with the 
indicated siRNAs and 24 h later they were exposed to 0.25 μM KPT-185 for 48 h. siNC, 
negative control siRNA. Mean and range (n = 2). f, Nuclear accumulation of IκBα in 
xenograft tumours in response to KPT-330 treatment. Scale bars, 50 μm.
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Figure 4. Concurrent mutations in FSTL5 are associated with intrinsic resistance of KRAS-
mutant lines to XPO1 inhibitors and are mechanistically coupled to YAP1 activation
a, Biclustering results for NSCLC cell lines and KRAS and FSTL5 mutation status. b, 
Selective effects of FSTL5 depletion on the XPO1-inhibitor-sensitivity of KRAS-mutant, 
FSTL5-wild-type lines (red) versus KRAS-mutant, FSTL5-mutant lines (green). Box plot 
indicates fold changes in area under the curve (AUC) of FSTL5 siRNA (siFSTL5)-
transfected cells normalized to negative control siRNA-transfected cells. AUCs calculated 
from Extended Data Fig. 5f, g. Unpaired t-test, P = 0.0411. c, Significant enrichment of 
YAP1 protein in tumours harbouring FSTL5 somatic alterations (data taken from the TCGA-
LUAD). Unpaired t-test, P = 0.0149. d, YAP1 protein accumulation 72 h post-transfection 
with FSTL5 siRNAs. e, YAP1 immunohistochemistry. Detected somatic FSTL5 variants are 
indicated. Representative YAP1 immunohistochemistry stains are shown in the right panel. f, 
Induction of XPO1-inhibitor resistance by YAP1 overexpression (crystal-violet stained). g, 
Induction of XPO1 inhibitors sensitivity by verteporfin/AICAR-mediated YAP pathway 
inhibition (crystal-violet stained).
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